Viibryd (vilazodone; Allergan) belongs to a new class of antidepressants, combining selective serotonin reuptake inhibitor activity with partial 5-HT1A receptor agonism, in order to produce its therapeutic effect. This differentiates Viibryd from a variety of older antidepressants that act purely through reuptake inhibition, although the exact contribution of Viibryd’s dual mechanism to its overall profile is not known.
Clinical Data, the company that progressed Viibryd through its clinical development, announced the drug’s US Food and Drug Administration approval in January 2011. Just three weeks later, Clinical Data reached an agreement with Forest Laboratories to enter into a definitive merger agreement worth approximately $1.2bn, depending upon contingent value rights. Viibryd was then launched by Forest in August 2011, although Forest itself was acquired by Allergan in 2014 for $25bn.
4 Drug Overview
5 Product Profiles
LIST OF FIGURES
5 Viibryd : Depression
12 Figure 1: Datamonitor Healthcare’s drug assessment summary of Viibryd for depression
13 Figure 2: Datamonitor Healthcare’s drug assessment summary of Viibryd for depression
15 Figure 3: Viibryd sales for depression in the US, 2017–26
LIST OF TABLES
6 Table 1: Viibryd drug profile
6 Table 2: Approval history of Viibryd for depression in the US
8 Table 3: Late-phase trials of Viibryd for depression
11 Table 4: Viibryd ongoing Phase III trials in depression
11 Table 5: Viibryd for depression – SWOT analysis
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.